Sun Pharma has agreed to acquire Organon for $11.75 billion in an all-cash deal valued at $14 per share, expanding its footprint in women’s health and biosimilars. The transaction follows Organon’s spinout from Merck in 2021 and is positioned as a portfolio and scale upgrade for Sun Pharma. For biotech and pharma investors, the deal signals continued consolidation in branded women’s health and growth in biosimilar-driven revenue strategies. It also highlights how large companies are using acquisitions to accelerate pipeline breadth rather than rely solely on internal R&D. The transaction’s headline terms—size, cash structure, and strategic categories—make it a near-term catalyst for competitive positioning across therapy areas where women’s health and copy biologics are expanding.